GLOBAL CANCER THERAPEUTICS AND BIOTHERAPEUTICS MARKET Size and trends

Global Cancer Therapeutics And Biotherapeutics Market Size and Trends

The Global Cancer Therapeutics and Biotherapeutics Market is estimated to be valued at USD 211.02 Bn in 2025 and is expected to reach USD 378.62 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 8.7% from 2025 to 2032. The market has been witnessing steady growth over the past few years owing to the rising awareness about healthcare associated infections and increasing prevalence of chronic diseases.

To learn more about this report, Request sample copy

The cancer therapeutics and biotherapeutics market is expected to witness a steady growth over the forecast period owing to the increasing prevalence of cancer worldwide. The rising need for the treatment of various types of cancer including blood cancer, breast cancer, lung cancer, prostate cancer, and colorectal cancer is expected to drive the demand for cancer therapeutics and biotherapeutics. Additionally, growing preference for targeted therapy over conventional chemotherapy is further expected to support the growth of this market during the forecast period. Increasing government initiatives to spread awareness about cancer and improve the access to early screening and diagnosis is also projected to propel the cancer therapeutics and biotherapeutics market growth between 2025 and 2032.

The rise of targeted therapy drugs

One of the key drivers of growth in the global cancer therapeutics and biotherapeutics market has been the rise of targeted therapy drugs. Traditional chemotherapy drugs aimed to destroy cancer cells but often damaged healthy cells as well, leading to harmful side effects. In recent years, breakthroughs in cancer research have led to the development of targeted drugs that home in on specific molecular targets found on cancer cells. These molecular targets could be overexpressed proteins on the cancer cell surface, mutated proteins driving cell growth and survival or changes to genes and chromosomes. Examples include trastuzumab for HER2-positive breast cancer, imatinib for chronic myeloid leukemia, and vemurafenib for melanoma with BRAF mutations. Targeted drugs are more precise than traditional chemotherapy in distinguishing cancer cells from normal cells. As a result, they can be more effective at killing cancer cells while reducing damage to healthy cells. This translates to improved clinical outcomes for patients such as higher response rates, longer duration of response, and sometimes even cure. Targeted drugs also tend to have milder and more tolerable side effect profiles compared to chemotherapy. Their improved efficacy and safety profiles have led to rapid uptake by oncologists and patients. With advances in diagnostic testing, more cancer driver mutations and biomarkers are being discovered each year, further expanding the pool of patients eligible for targeted therapies. Drug companies have also made huge investments in developing new targeted agents, bringing multiple new pipeline drugs to market annually. All of these factors have combined to power strong growth in the targeted therapy segment.